Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17

Shire324 enrolled

Overview

The purpose of this study is to determine the efficacy of SPD503 compared to placebo in the treatment of children and adolescents aged 6-17 with ADHD.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

324

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

SPD503 (1 mg)DRUG

SPD503 (2 mg)DRUG

SPD503 (3 mg)DRUG

SPD503 (4 mg)DRUG

Eligibility

Sex: ALLMin age: 6 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with a primary diagnosis of ADHD * Females of childbearing potential must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test * Male or non-pregnant female subject who agrees to comply with any applicable contraceptive requirements Exclusion Criteria: * Subject has a current, uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as severe comorbid Axis II disorders or severe Axis I disorders * Subject weighs less than 55 lbs or is morbidly overweight with a BMI =\> 35 * Subject has a history of seizure during the last 2 years or a serious tic disorder, including Tourette's Disorder * Subject is pregnant or lactating

Outcomes

Primary Outcomes

Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Score at 6 Weeks

Change in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth edition (ADHD-RS-IV) total score from baseline. The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.

Time frame: Baseline and 6 weeks

Secondary Outcomes

Change From Baseline in Conner's Parent Rating Scale-revised Short Version (CPRS-R) Score at 6 Weeks

The Conner's Parent rating Scale-revised short version (CPRS-R) consists of 27 questions graded on a scale from 0 (not true at all) to 3 (very much true) with a total score ranging from 0 to 81. Higher scores are indicative of increased ADHD. This scale allows parents to respond on the basis of the child's behavior and help assess ADHD and evaluate problem behavior.

Time frame: Baseline and 6 weeks

Number of Participants With Improvement in Clinical Global Impression-Improvement (CGI-I)

Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

Time frame: 6 weeks

Number of Participants With Improvement in Parent Global Assessment (PGA)

Parent Global Assessment (PGA) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

Time frame: 6 weeks

Change From Baseline in Child Health Questionnaire-Parent Form (CHQ-PF50) Score at 6 Weeks

The Child Health Questionnaire-Parent Form (CHQ-PF50) was developed to measure the physical and psychosocial well-being of children aged 5 years of age and older. Total scoring ranges from 0-100. Increases in scores represent improved well-being in subjects as assessed by their parents.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.